These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 17197372)

  • 1. Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms.
    Coyle JT
    Neurotox Res; 2006 Dec; 10(3-4):221-33. PubMed ID: 17197372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.
    Coyle JT; Tsai G
    Psychopharmacology (Berl); 2004 Jun; 174(1):32-8. PubMed ID: 15205876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substance abuse and schizophrenia: pharmacotherapeutic intervention.
    Green AI; Noordsy DL; Brunette MF; O'Keefe C
    J Subst Abuse Treat; 2008 Jan; 34(1):61-71. PubMed ID: 17574793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate and schizophrenia: beyond the dopamine hypothesis.
    Coyle JT
    Cell Mol Neurobiol; 2006; 26(4-6):365-84. PubMed ID: 16773445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.
    Kawaura K; Koike H; Kinoshita K; Kambe D; Kaku A; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2015 Feb; 278():186-92. PubMed ID: 25300471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
    Shim SS; Hammonds MD; Kee BS
    Eur Arch Psychiatry Clin Neurosci; 2008 Feb; 258(1):16-27. PubMed ID: 17901997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-serine added to clozapine for the treatment of schizophrenia.
    Tsai GE; Yang P; Chung LC; Tsai IC; Tsai CW; Coyle JT
    Am J Psychiatry; 1999 Nov; 156(11):1822-5. PubMed ID: 10553752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.
    Millan MJ
    Psychopharmacology (Berl); 2005 Apr; 179(1):30-53. PubMed ID: 15761697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia.
    Coyle JT; Tsai G; Goff D
    Ann N Y Acad Sci; 2003 Nov; 1003():318-27. PubMed ID: 14684455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ionotropic glutamate receptors as therapeutic targets in schizophrenia.
    Coyle JT; Tsai G; Goff DC
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):183-9. PubMed ID: 12769626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action.
    Zhou X; Cai G; Mao S; Xu D; Xu X; Zhang R; Yao Z
    BMC Psychiatry; 2020 Mar; 20(1):106. PubMed ID: 32143671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of
    Goh KK; Wu TH; Chen CH; Lu ML
    J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine.
    Malhotra AK; Adler CM; Kennison SD; Elman I; Pickar D; Breier A
    Biol Psychiatry; 1997 Oct; 42(8):664-8. PubMed ID: 9325559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D-Serine and a glycine transporter-1 inhibitor enhance social memory in rats.
    Shimazaki T; Kaku A; Chaki S
    Psychopharmacology (Berl); 2010 Apr; 209(3):263-70. PubMed ID: 20198471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA(B) receptors in nucleus accumbens neurons.
    Berton F; Francesconi WG; Madamba SG; Zieglgänsberger W; Siggins GR
    Alcohol Clin Exp Res; 1998 Feb; 22(1):183-91. PubMed ID: 9514305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
    Singh SP; Singh V
    CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Lane HY; Yang P; Chong MY; Lange N
    Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.